CNAT:NSD-Conatus Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 5.56

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

1.70M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-06 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD55.11B 20.60 15.08
MRNA Moderna, Inc

N/A

USD52.85B N/A N/A
REGN Regeneron Pharmaceuticals, Inc

N/A

USD49.45B 15.12 11.87
ALXN Alexion Pharmaceuticals, Inc

N/A

USD33.00B 55.18 32.28
BGNE BeiGene, Ltd

N/A

USD28.45B N/A N/A
SGEN Seagen Inc

N/A

USD27.06B 44.32 37.70
RPRX Royalty Pharma plc

N/A

USD25.83B 22.60 15.41
BNTX BioNTech SE

N/A

USD23.16B -99,999.99 N/A
GMAB Genmab A/S

N/A

USD20.42B 26.59 3.20
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CNAT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -85.74% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.74% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -97.52% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.52% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -15.84% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.84% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 93.24% N/A N/A N/A N/A
Risk Adjusted Return -16.99% N/A N/A N/A N/A
Market Capitalization 0.02B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.05 N/A N/A N/A N/A
Price / Cash Flow Ratio -0.91 N/A N/A N/A N/A
EV/EBITDA 0.19 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -49.07% N/A N/A N/A N/A
Return on Invested Capital -50.46% N/A N/A N/A N/A
Return on Assets -21.85% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.37 N/A N/A N/A N/A
Short Percent 0.41% N/A N/A N/A N/A
Beta 1.84 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.